Atria Wealth Solutions Inc. Cuts Stock Position in West Pharmaceutical Services, Inc. $WST

Atria Wealth Solutions Inc. lowered its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 72.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,123 shares of the medical instruments supplier’s stock after selling 2,898 shares during the period. Atria Wealth Solutions Inc.’s holdings in West Pharmaceutical Services were worth $246,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Astoria Portfolio Advisors LLC. purchased a new position in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $189,000. Sequoia Financial Advisors LLC grew its position in shares of West Pharmaceutical Services by 102.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,356 shares of the medical instruments supplier’s stock worth $516,000 after buying an additional 1,192 shares during the last quarter. Vest Financial LLC grew its position in shares of West Pharmaceutical Services by 54.1% in the 2nd quarter. Vest Financial LLC now owns 244,814 shares of the medical instruments supplier’s stock worth $53,565,000 after buying an additional 85,897 shares during the last quarter. Yousif Capital Management LLC grew its position in shares of West Pharmaceutical Services by 7.6% in the 2nd quarter. Yousif Capital Management LLC now owns 31,202 shares of the medical instruments supplier’s stock worth $6,827,000 after buying an additional 2,202 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of West Pharmaceutical Services by 13.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,592 shares of the medical instruments supplier’s stock worth $799,000 after buying an additional 420 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $276.87 on Thursday. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $352.33. The company has a 50 day simple moving average of $257.04 and a two-hundred day simple moving average of $232.65. The stock has a market cap of $19.91 billion, a price-to-earnings ratio of 41.45, a PEG ratio of 4.90 and a beta of 1.07.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, beating the consensus estimate of $1.51 by $0.33. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The business had revenue of $766.50 million during the quarter, compared to analysts’ expectations of $725.11 million. During the same period in the previous year, the business posted $1.52 EPS. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. As a group, analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on WST. Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Tuesday, October 14th. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. UBS Group boosted their target price on shares of West Pharmaceutical Services from $285.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Finally, Rothschild Redb raised shares of West Pharmaceutical Services to a “strong-buy” rating in a research report on Monday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and a consensus target price of $321.89.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.